Tyra Biosciences (TYRA) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing dabogratinib, a first-in-class, highly selective oral FGFR3 inhibitor, for three major indications: intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), low-grade upper tract urothelial carcinoma (LG UTUC), and achondroplasia (ACH).

• FGFR3 alterations are validated drivers in these diseases, representing significant unmet needs and large addressable markets in oncology and skeletal dysplasia.

• Cash position of $353.9M as of 2Q26 supports ongoing and planned pivotal trials.

Clinical development and efficacy data

• SURF302 Phase 2 trial in IR NMIBC showed 79% overall response rate (ORR) and 64% complete response (CR) at 60mg, with 100% ORR and 75% CR in single marker lesion patients.

• Safety profile supports chronic dosing, with manageable adverse events and no grade 4/5 toxicities.

• Modeling suggests efficacy plateaus above 60mg, supporting this dose for Phase 3 adjuvant studies.

• First LG UTUC patient dosed in Phase 2, with early evidence of complete response and no significant adverse events.

Market opportunity and patient needs

• IR NMIBC and LG UTUC represent large US markets, with ~35,000 and ~3,000 FGFR3+ patients seeking new treatment annually, respectively.

• Most IR NMIBC patients currently forego adjuvant therapy due to inconvenience and invasiveness of current options.

• Surveys indicate strong patient and urologist preference for an effective, convenient oral therapy over invasive procedures.

• Estimated full potential FGFR3+ IR NMIBC market exceeds $5 billion.